Therefore, 1st and 2nd generation EGFR-TKIs have been widely used as first-line standard treatment for advanced NSCLC patients with sensitive EGFR mutations (L858R or exon 19 deletion). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.